Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension-Reference-Cited by-同舟云学术

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

Published:2017-11-22 Issue:2 Volume:33 Page:190-198
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Cummings Steven R¹,Ferrari Serge²,Eastell Richard³,Gilchrist Nigel⁴,Jensen Jens-Erik Beck⁵,McClung Michael⁶,Roux Christian⁷,Törring Ove⁸,Valter Ivo⁹,Wang Andrea T¹⁰,Brown Jacques P¹¹

Affiliation:

1. San Francisco Coordinating Center; CPMC Research Institute; San Francisco CA USA

2. Geneva University Hospital; Geneva Switzerland

3. The University of Sheffield; Sheffield UK

4. The Princess Margaret Hospital; Christchurch New Zealand

5. Hvidovre University Hospital; Hvidovre Denmark

6. Oregon Osteoporosis Center; Portland OR USA

7. Paris Descartes University; Paris France

8. Karolinska Institutet; Södersjukhuset Stockholm Sweden

9. Center for Clinical and Basic Research; Tallinn Estonia

10. Amgen Inc.; Thousand Oaks; CA USA

11. Laval University and CHU de Québec-Université Laval (CHUL); Quebec City Canada

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jbmr.3337/fullpdf

Reference18 articles.

1. Denosumab for prevention of fractures in postmenopausal women with osteoporosis;Cummings;N Engl J Med,2009

2. Denosumab in postmenopausal women with low bone mineral density;McClung;N Engl J Med,2006

3. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension;Bone;J Clin Endocrinol Metab,2013

4. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years;Ferrari;Osteoporos Int,2015

5. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension;Papapoulos;J Bone Miner Res,2012

Cited by 510 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of choroidal osteoma progression using bisphosphonate and RANKL-inhibitory treatment;American Journal of Ophthalmology Case Reports;2024-12

2. The use of denosumab in osteoporosis – an update on efficacy and drug safety;Expert Opinion on Drug Safety;2024-09-11

3. Hydroxychloroquine and a low antiresorptive activity bisphosphonate conjugate prevent and reverse ovariectomy-induced bone loss in mice through dual antiresorptive and anabolic effects;Bone Research;2024-09-05

4. Bone Metabolism, Bone Mass, and Bone Structure During Pregnancy and Lactation;Endocrinology and Metabolism Clinics of North America;2024-09

5. Advances in mechanobiological pharmacokinetic-pharmacodynamic models of osteoporosis treatment – Pathways to optimise and exploit existing therapies;Bone;2024-09